ArticleEuropean archives of psychiatry and clinical neuroscience2026
Hyperhomocysteinemia in chronic schizophrenia: prevalence, clinical correlates, and paradoxical associations with symptom severity.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundElevated homocysteine levels, known as hyperhomocysteinemia (HHcy), have been implicated in the pathophysiology of schizophrenia. Most prior studies focused on first-episode or acute-phase schizophrenia patients, leaving the prevalence, determinants, and clinical correlates of HHcy in chronic schizophrenia understudied. This study aims to investigate the prevalence and determinants of HHcy in patients with chronic schizophrenia, as well as its clinical correlates.
methodsA cross-sectional study was conducted involving 509 patients diagnosed with chronic schizophrenia, recruited from multiple psychiatric hospitals in China. Demographic, clinical, and lifestyle data were collected through structured interviews and medical record reviews. Blood samples were analyzed for homocysteine levels and other biochemical parameters. The Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale (HAMD), Insomnia Severity Index (ISI), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were used to assess clinical symptoms and cognitive function. Binary logistic regression analysis was performed to identify independent predictors of HHcy. RESULTS: The prevalence of HHcy in the study population was 56.2%. Patients with HHcy were significantly older (mean age: 52.1 ± 12.2 years) and had a higher proportion of males (67.1%) compared to those without HHcy. The HHcy group exhibited milder positive and general psychopathology symptoms, as indicated by lower PANSS scores, revealing unexpected inverse associations with symptom severity. Elevated levels of C-reactive protein (CRP), total bilirubin (TBIL), and creatine phosphokinase (CPK) were observed in the HHcy group. Binary logistic regression analysis identified female gender and older age as independent predictors of HHcy.
conclusionsThis study highlights a high prevalence of HHcy in patients with chronic schizophrenia, associated with older age and male gender. Contrary to expectations, HHcy was linked to milder symptom severity, suggesting a potential paradoxical relationship.
Indexed as
Identifiers
40924104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.